ZFIN ID: ZDB-FISH-150901-2166
Fish name: gz15Tg
Genotype: gz15Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gz15Tg
Human Disease Conditions Citations
non-alcoholic fatty liver disease chemical treatment by diet: fructose Yan et al., 2017
chemical treatment by diet: cholesterol Yan et al., 2017
GENE EXPRESSION
Gene expression in gz15Tg
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab-2F11 standard conditions Fig. 4 with image from Zhang et al., 2014
Fig. 2 from Curado et al., 2010
Fig. 3 with image from Noël et al., 2008
Fig. 1Fig. 3 from Dong et al., 2007
Ab2-lepa chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
Ab6-pcna chemical treatment: doxycycline Fig. 4 with image from Yan et al., 2017
Ab1-tgfb1a chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
ab1-sst standard conditions Fig. 1 from Dong et al., 2007
Ab29-mapk chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
Ab4-tjp1 standard conditions Fig. 4 with image from Zhang et al., 2017
Ab7-h3 standard conditions Fig. 5 with image from Anderson et al., 2009
Ab-WCL15 standard conditions Fig. 2Fig. 3 from Curado et al., 2010
Ab5-pcna chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate Fig. 5 with image from Yan et al., 2015
Ab1-casp3 chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate Fig. 5 with image from Yan et al., 2015
Ab-smad2 chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
Ab1-pan-Cadherin standard conditions Fig. 1 from Dong et al., 2008
Ab1-dnmt1 dnmt1 standard conditions Fig. 3 with imageFig. 5 with image from Anderson et al., 2009
Ab3-prox1 prox1a standard conditions Fig. 4 with image from Zhang et al., 2017
PHENOTYPE
Phenotype in gz15Tg
Phenotype Conditions Figures
cleithrum bone mineralization increased occurrence, abnormal chemical treatment by environment: osteogenesis regulator Fig. 6 with image from Bae et al., 2017
hepatocyte ab-smad2 labeling amount, ameliorated chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor Fig. 2 from Yan et al., 2017
hepatocyte Ab29-mapk labeling amount, ameliorated chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling amount, ameliorated chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor Fig. 2 from Yan et al., 2017
hepatocyte tnfa expression increased amount, abnormal chemical treatment by diet: fructose Fig. 1 from Yan et al., 2017
hepatocyte tnfa expression increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor Fig. 2 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal chemical treatment by diet: cholesterol, chemical treatment: LY294002 Fig. 2 from Yan et al., 2017
hepatocyte srebf1 expression increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1 from Yan et al., 2017
hepatocyte srebf1 expression increased amount, abnormal chemical treatment by diet: fructose Fig. 1 from Yan et al., 2017
hepatocyte il1b expression increased amount, abnormal chemical treatment by diet: fructose Fig. 1 from Yan et al., 2017
hepatocyte tgfb1a expression increased amount, abnormal chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
hepatocyte il1b expression increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1 from Yan et al., 2017
hepatocyte nfkb2 expression increased amount, abnormal chemical treatment by diet: glucose Fig. 1 from Yan et al., 2017
hepatocyte Ab29-mapk labeling increased amount, abnormal chemical treatment by diet: cholesterol, chemical treatment: LY294002 Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling increased amount, abnormal chemical treatment by diet: cholesterol, chemical treatment: LY294002 Fig. 2 from Yan et al., 2017
hepatocyte cebpa expression increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1 from Yan et al., 2017
hepatocyte cebpa expression increased amount, abnormal chemical treatment by diet: fructose Fig. 1 from Yan et al., 2017
hepatocyte pparg expression increased amount, abnormal chemical treatment by diet: glucose Fig. 1 from Yan et al., 2017
hepatocyte ab-smad2 labeling increased amount, abnormal chemical treatment by diet: cholesterol, chemical treatment: LY294002 Fig. 2 from Yan et al., 2017
hepatocyte tnfa expression increased amount, abnormal chemical treatment by diet: glucose Fig. 1 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
hepatocyte srebf1 expression increased amount, abnormal chemical treatment by diet: glucose Fig. 1 from Yan et al., 2017
hepatocyte il1b expression increased amount, abnormal chemical treatment by diet: glucose Fig. 1 from Yan et al., 2017
hepatocyte tgfb1a expression increased amount, abnormal chemical treatment by diet: glucose Fig. 2 from Yan et al., 2017
hepatocyte lepa expression increased amount, abnormal chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
hepatocyte Ab29-mapk labeling increased amount, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2017
hepatocyte lepa expression increased amount, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2017
hepatocyte Ab29-mapk labeling increased amount, abnormal chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
hepatocyte nfkb2 expression increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1 from Yan et al., 2017
hepatocyte nfkb2 expression increased amount, abnormal chemical treatment by diet: fructose Fig. 1 from Yan et al., 2017
hepatocyte ab-smad2 labeling increased amount, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling increased amount, abnormal chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling increased amount, abnormal chemical treatment by diet: cholesterol Fig. 2 from Yan et al., 2017
hepatocyte cebpa expression increased amount, abnormal chemical treatment by diet: glucose Fig. 1 from Yan et al., 2017
hepatocyte pparg expression increased amount, abnormal chemical treatment by diet: cholesterol Fig. 1 from Yan et al., 2017
hepatocyte pparg expression increased amount, abnormal chemical treatment by diet: fructose Fig. 1 from Yan et al., 2017
hepatocyte ab-smad2 labeling increased amount, abnormal chemical treatment by diet: fructose Fig. 2 from Yan et al., 2017
hepatocyte inflammatory response increased process quality, abnormal chemical treatment by diet: fructose Fig. 1 from Yan et al., 2017
hepatocyte inflammatory response increased process quality, abnormal chemical treatment by diet: cholesterol Fig. 1 from Yan et al., 2017
liver increased size, abnormal chemical treatment: ethanol Fig. 1 with image from Tsedensodnom et al., 2013
liver mislocalised, abnormal chemical treatment: SU5402 Fig. 6 with image from Qian et al., 2013
liver mislocalised, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from Qian et al., 2013
male organism hepatocyte htr2b expression increased amount, abnormal standard conditions Fig. 3 with image from Yang et al., 2017
Meckel's cartilage bone mineralization increased occurrence, abnormal chemical treatment by environment: osteogenesis regulator Fig. 6 with image from Bae et al., 2017
palatoquadrate arch bone mineralization increased occurrence, abnormal chemical treatment by environment: osteogenesis regulator Fig. 6 with image from Bae et al., 2017
pericardium edematous, abnormal chemical treatment: ethanol Fig. 1 with image from Tsedensodnom et al., 2013
trunk curved dorsal, abnormal chemical treatment: ethanol Fig. 1 with image from Tsedensodnom et al., 2013
vertebra bone mineralization increased occurrence, abnormal chemical treatment by environment: osteogenesis regulator Fig. 6 with image from Bae et al., 2017

CITATIONS  (56)